Results 41 to 50 of about 10,329 (179)

Epigenetic control of CD1D expression as a mechanism of resistance to immune checkpoint therapy in poorly immunogenic melanomas

Frontiers in Immunology, 2023
Immune Checkpoint Therapies (ICT) have revolutionized the treatment of metastatic melanoma. However, only a subset of patients reaches complete responses. Deficient β2-microglobulin (β2M) expression impacts antigen presentation to T cells, leading to ICT
Mona Meng Wang, Mona Meng Wang, Saara A. Koskela, Arfa Mehmood, Miriam Langguth, Eleftheria Maranou, Carlos R. Figueiredo, Carlos R. Figueiredo   +7 more
doaj   +1 more source

Extended routine lymphocyte immunophenotyping refines individual immune organization across a heterogeneous patient cohort

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Routine TBNK immunophenotyping detects the major lymphocyte compartments but may underestimate the biologically relevant variation contributed by less frequent but well‐defined minor lymphocyte subsets. This study evaluated whether extending routine TBNK immunophenotyping with minor lymphocyte subsets provides complementary, analytically ...
Carlos Agustin Villegas Valverde, Yendry Ventura Carmenate, Vianed Marsan Suarez, Yandy Marx Castillo Aleman, Imilla Casado Hernandez, Rachely Hernandez Corrales   +5 more
wiley   +1 more source

CD1d affects the proliferation, migration, and apoptosis of human papillary thyroid carcinoma TPC-1 cells via regulating MAPK/NF-κB signaling pathway

Open Medicine
The study aimed to investigate the effect of CD1d down-regulation on the proliferation, migration, and apoptosis of papillary thyroid carcinoma cells and explore the underlying mechanism.
Liu Qingyuan, Zhai Tong, Ma Lei, Liu Qilun   +3 more
doaj   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, EarlyView.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

CD1d Activation and Blockade: A New Antitumor Strategy [PDF]

The Journal of Immunology, 2009
Abstract CD1d is expressed on APCs and presents glycolipids to CD1d-restricted NKT cells. For the first time, we demonstrate the ability of anti-CD1d mAbs to inhibit the growth of different CD1d-negative experimental carcinomas in mice.
Teng, Michele W. L., Yue, Simon, Sharkey, Janelle, Exley, Mark A., Smyth, Mark J.   +4 more
openaire   +4 more sources

Alternative spliced CD1d transcripts in human bronchial epithelial cells.

PLoS ONE, 2011
CD1d is a MHC I like molecule which presents glycolipid to natural killer T (NKT) cells, a group of cells with diverse but critical immune regulatory functions in the immune system.
Kambez Hajipouran Benam, Wai Ling Kok, Andrew J McMichael, Ling-Pei Ho   +3 more
doaj   +1 more source

Defining Composition–Cytokine Relationships Enables the Design of Lipid Nanoparticles with Programmed Immunogenicity

Small, EarlyView.
Lipid nanoparticle composition governs distinct cytokine programs through the interplay of ionizable and polyethylene glycol‐conjugated (PEGylated) lipids. In vitro profiling, design of experiments (DoE) modeling, and in vivo validation reveal how formulation can tune reactogenicity‐associated pathways, while transgene expression remains the strongest ...
Adam Alexander Walters, Belal I. Hanafy, Chuan‐En Lu, Sara Marelli, Alaa Zam, Kai Liu, Rachel E. Foreman, Ramesh Soundararajan, Philippe Collin, Lennart Lindfors, Alan Sabirsh, Mariarosa Mazza, Khuloud T. Al‐Jamal, Stephanie M. Bates, George Thom, Jan Rehwinkel, Alexander N Kapustin   +16 more
wiley   +1 more source

CD1d Ligands: The Good, the Bad, and the Ugly [PDF]

The Journal of Immunology, 2006
Abstract The MHC class I-like CD1d glycoprotein is a member of the CD1 family of Ag-presenting molecules and is responsible for the selection of NKT cells. A number of ligands that can be presented by CD1d to NKT or other CD1d-restricted T cells have been identified.
openaire   +2 more sources

CD1d- and MR1-Restricted T Cells in Sepsis [PDF]

Frontiers in Immunology, 2015
Dysregulated immune responses to infection, such as those encountered in sepsis, can be catastrophic. Sepsis is typically triggered by an overwhelming systemic response to an infectious agent(s) and is associated with high morbidity and mortality even under optimal critical care. Recent studies have implicated unconventional, innate-like T lymphocytes,
Peter A. Szabo, Ram V. Anantha, Ram V. Anantha, Christopher R. Shaler, John K. McCormick, S.M. Mansour eHaeryfar, S.M. Mansour eHaeryfar   +6 more
openaire   +3 more sources

Mouse and Human CD1d-Self-Lipid Complexes Are Recognized Differently by Murine Invariant Natural Killer T Cell Receptors.

PLoS ONE, 2016
Invariant natural killer T (iNKT) cells recognize self-lipids presented by CD1d through characteristic TCRs, which mainly consist of the invariant Vα14-Jα18 TCRα chain and Vβ8.2, 7 or 2 TCRβ chains with hypervariable CDR3β sequences in mice.
Tingxi Guo, Kenji Chamoto, Munehide Nakatsugawa, Toshiki Ochi, Yuki Yamashita, Mark Anczurowski, Marcus O Butler, Naoto Hirano   +7 more
doaj   +1 more source